JP2005523271A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523271A5 JP2005523271A5 JP2003565487A JP2003565487A JP2005523271A5 JP 2005523271 A5 JP2005523271 A5 JP 2005523271A5 JP 2003565487 A JP2003565487 A JP 2003565487A JP 2003565487 A JP2003565487 A JP 2003565487A JP 2005523271 A5 JP2005523271 A5 JP 2005523271A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- group
- formula
- receptor antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- -1 5, 6,7,8-tetrahydronaphthalenyl Chemical group 0.000 claims 11
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 10
- 239000003149 muscarinic antagonist Substances 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 230000000241 respiratory effect Effects 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- 125000002723 alicyclic group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000007789 gas Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000003380 propellant Substances 0.000 claims 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 102000017927 CHRM1 Human genes 0.000 claims 1
- 102000017926 CHRM2 Human genes 0.000 claims 1
- 102000017925 CHRM3 Human genes 0.000 claims 1
- 101150060249 CHRM3 gene Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 101150073075 Chrm1 gene Proteins 0.000 claims 1
- 101150012960 Chrm2 gene Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000006267 biphenyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical group O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims 1
- 229960001888 ipratropium Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 claims 1
- 229960000797 oxitropium Drugs 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical group O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims 1
- 229940110309 tiotropium Drugs 0.000 claims 1
- 239000000273 veterinary drug Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0202635.9A GB0202635D0 (en) | 2002-02-05 | 2002-02-05 | Formulation containing novel anti-inflammatory androstane derivative |
| PCT/GB2003/000491 WO2003066063A1 (en) | 2002-02-05 | 2003-02-04 | Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothioate androstanes with a muscarinic receptor antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005523271A JP2005523271A (ja) | 2005-08-04 |
| JP2005523271A5 true JP2005523271A5 (enExample) | 2006-01-05 |
| JP4613010B2 JP4613010B2 (ja) | 2011-01-12 |
Family
ID=9930430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565487A Expired - Lifetime JP4613010B2 (ja) | 2002-02-05 | 2003-02-04 | １７β−カルボチオ酸アンドロスタンの１７α−フラニルエステルをムスカリン受容体アンタゴニストと共に含む医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20060002861A1 (enExample) |
| EP (1) | EP1471919B1 (enExample) |
| JP (1) | JP4613010B2 (enExample) |
| AT (1) | ATE301463T1 (enExample) |
| AU (1) | AU2003208395A1 (enExample) |
| DE (1) | DE60301261T2 (enExample) |
| ES (1) | ES2246466T3 (enExample) |
| GB (1) | GB0202635D0 (enExample) |
| WO (1) | WO2003066063A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
| GB0602980D0 (en) * | 2006-02-14 | 2006-03-29 | Optinose As | Delivery device and method |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| WO2012009609A1 (en) | 2010-07-15 | 2012-01-19 | Battelle Memorial Institute | Biobased polyols for potential use as flame retardants in polyurethane and polyester applications |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
| US9962462B2 (en) * | 2015-06-11 | 2018-05-08 | Case Western Reserve University | Dry spray on hemostatic system |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2837464A (en) * | 1955-01-11 | 1958-06-03 | Schering Corp | Process for production of dienes by corynebacteria |
| US2816902A (en) * | 1957-01-14 | 1957-12-17 | Schering Corp | Hydroxylated steroids |
| US3067197A (en) * | 1961-04-26 | 1962-12-04 | Pfizer & Co C | 11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives |
| GB1047518A (en) * | 1963-06-11 | 1966-11-02 | Glaxo Lab Ltd | 17ª-monoesters of 11,17,21-trihydroxy steroid compounds |
| GB1158492A (en) * | 1966-02-09 | 1969-07-16 | Boots Pure Drug Co Ltd | Improvements in Acylated Steroids |
| US3639434A (en) * | 1967-02-02 | 1972-02-01 | Boots Pure Drug Co Ltd | 17-acyloxysteroids and their manufacture |
| GB1227992A (enExample) * | 1968-01-23 | 1971-04-15 | Koninklijke Gist Spiritus | |
| IT1034011B (it) * | 1969-06-26 | 1979-09-10 | Vister Vismara Terapeutici S P | Processo per la prapratzione di 17 monoesteri di 17 a 21 diossisteroidi per idrolisi die corpispondenti 17 21 ortoesteri ciclici a ph control lato |
| US3828080A (en) * | 1972-01-20 | 1974-08-06 | Glaxo Lab Ltd | Androstane-17beta-carboxylic acids and processes for the preparation thereof |
| US3989686A (en) * | 1972-06-15 | 1976-11-02 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstane series and process for preparing same |
| GB1438940A (en) * | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
| GB1440063A (en) * | 1972-08-11 | 1976-06-23 | Glaxo Lab Ltd | 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids |
| GB1517278A (en) * | 1974-08-30 | 1978-07-12 | Glaxo Lab Ltd | Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates |
| US4093721A (en) * | 1974-08-30 | 1978-06-06 | Glaxo Laboratories Limited | Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof |
| YU54476A (en) * | 1975-03-31 | 1982-05-31 | Taisho Pharmaceutical Co Ltd | Process for obtaining 17-ester 21-halo-pregnane |
| CH628355A5 (de) * | 1976-02-24 | 1982-02-26 | Ciba Geigy Ag | Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze. |
| US4221787A (en) * | 1978-03-28 | 1980-09-09 | Interx Research Corporation | Esteramide prodrugs of anti-inflammatory corticosteroids |
| US4188385A (en) * | 1978-04-05 | 1980-02-12 | Syntex (U.S.A.) Inc. | Thioetianic acid derivatives |
| US4261984A (en) * | 1978-04-05 | 1981-04-14 | Syntex (U.S.A.) Inc. | 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes |
| US4263289A (en) * | 1978-04-05 | 1981-04-21 | Syntex (U.S.A.) Inc. | Thio etianic acid derivatives |
| US4187301A (en) * | 1978-04-05 | 1980-02-05 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes |
| US4198403A (en) * | 1978-04-05 | 1980-04-15 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes |
| DE2817988A1 (de) * | 1978-04-25 | 1979-11-08 | Hoechst Ag | Corticoid 17-alkylcarbonate und verfahren zu deren herstellung |
| US4310466A (en) * | 1979-08-31 | 1982-01-12 | Syntex (U.S.A.) Inc. | Thio etianic acid derivatives |
| US4267173A (en) * | 1979-11-05 | 1981-05-12 | Schering Corporation | Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor |
| ZA81976B (en) * | 1980-02-15 | 1982-07-28 | Glaxo Group Ltd | Androstane carbothioates |
| US4996335A (en) * | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| US4710495A (en) * | 1980-07-10 | 1987-12-01 | Otsuka Pharmaceutical Co., Ltd. | Soft steroids having anti-inflammatory activity |
| ATE8790T1 (de) * | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| US4607028A (en) * | 1983-08-18 | 1986-08-19 | Ciba-Geigy Corporation | Novel carboxylic acid esters |
| US4861765A (en) * | 1985-06-26 | 1989-08-29 | Jouveinal | 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them |
| US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| US5202316A (en) * | 1989-03-22 | 1993-04-13 | Roussel Uclaf | N,N,N',N'-6-(1-piperazinyl)-2,5-pyridinediamines |
| FR2644788B1 (fr) * | 1989-03-22 | 1995-02-03 | Roussel Uclaf | Nouveaux steroides 3-ceto comportant une chaine en 17 amino-substituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant |
| JPH07116215B2 (ja) * | 1989-04-19 | 1995-12-13 | エスエス製薬株式会社 | 新規なステロイド化合物 |
| DE3931041C2 (de) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| DE4025342A1 (de) * | 1990-08-10 | 1992-02-13 | Hoechst Ag | In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
| US5250293A (en) * | 1991-04-22 | 1993-10-05 | Gleich Gerald J | Method for the treatment of hypersensitivity diseases by administration of anionic polymers |
| US6127353A (en) * | 1991-09-06 | 2000-10-03 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
| US5658549A (en) * | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
| DE4328819A1 (de) * | 1993-08-27 | 1995-03-02 | Hoechst Ag | Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| DE4333920A1 (de) * | 1993-10-05 | 1995-04-13 | Hoechst Ag | Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| US5420120A (en) * | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
| US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| GB9419536D0 (en) * | 1994-09-28 | 1994-11-16 | Glaxo Inc | Medicaments |
| DE19528145A1 (de) * | 1995-08-01 | 1997-02-06 | Boehringer Ingelheim Kg | Neue Arzneimittel und ihre Verwendung |
| US5707984A (en) * | 1995-12-08 | 1998-01-13 | G. D. Searle & Co. | Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs |
| SI0876392T1 (en) * | 1995-12-29 | 2000-12-31 | Glaxo Group Limited | Lactone derivatives of 17.beta.-carboxy, carbothio and amide androstane derivatives |
| US5981517A (en) * | 1996-05-09 | 1999-11-09 | Soft Drugs, Inc. | Androstene derivatives |
| US5919776A (en) * | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
| US5972920A (en) * | 1998-02-12 | 1999-10-26 | Dermalogix Partners, Inc. | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
| US6136294C1 (en) * | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
| US6261539B1 (en) * | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
| US6623760B1 (en) * | 1999-01-28 | 2003-09-23 | Schering Corporation | Method of preparing particles for agglomeration |
| ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US20020081266A1 (en) * | 1999-08-20 | 2002-06-27 | Norton Healthcare Ltd. | Spray dried powders for pulmonary or nasal administration |
| GB0009606D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
| GB0009592D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
| GB0009583D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| GB0015876D0 (en) * | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| US6777400B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858593B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| CA2417826A1 (en) * | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| US6787532B2 (en) * | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6750210B2 (en) * | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US20020183292A1 (en) * | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
| CN101518537A (zh) * | 2000-12-22 | 2009-09-02 | 日本新药株式会社 | 炎症性呼吸道疾病的预防/治疗剂 |
| US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| JP3691459B2 (ja) * | 2002-06-14 | 2005-09-07 | 久光メディカル株式会社 | 粉末状吸入剤組成物 |
-
2002
- 2002-02-05 GB GBGB0202635.9A patent/GB0202635D0/en not_active Ceased
-
2003
- 2003-02-04 ES ES03706683T patent/ES2246466T3/es not_active Expired - Lifetime
- 2003-02-04 AU AU2003208395A patent/AU2003208395A1/en not_active Abandoned
- 2003-02-04 JP JP2003565487A patent/JP4613010B2/ja not_active Expired - Lifetime
- 2003-02-04 US US10/502,966 patent/US20060002861A1/en not_active Abandoned
- 2003-02-04 EP EP03706683A patent/EP1471919B1/en not_active Expired - Lifetime
- 2003-02-04 WO PCT/GB2003/000491 patent/WO2003066063A1/en not_active Ceased
- 2003-02-04 DE DE60301261T patent/DE60301261T2/de not_active Expired - Lifetime
- 2003-02-04 AT AT03706683T patent/ATE301463T1/de not_active IP Right Cessation
-
2012
- 2012-08-24 US US13/593,816 patent/US20120321565A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003123120A (ru) | Новые производные хинуклидина и содержащие их лекарственные композиции | |
| RU2002103605A (ru) | Производные хинуклидина и их применение в качестве лигандов мускаринового рецептора МЗ | |
| JP4612956B2 (ja) | 抗コリン作用化合物及びβ−擬似剤に基づく新規医薬組成物 | |
| JP4030040B2 (ja) | キヌクリジン誘導体およびそれらのムスカリンｍ３レセプターリガンドとしての使用 | |
| JP2005533826A5 (enExample) | ||
| JP2005527496A5 (enExample) | ||
| CA2496699A1 (en) | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids | |
| JP2005523271A5 (enExample) | ||
| RU2013119938A (ru) | Фармацевтическая композиция | |
| WO2005070429A1 (en) | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist | |
| JP2005533799A5 (enExample) | ||
| RU2008124833A (ru) | Лечение астмы и хронического обструктивного заболевания легких с использованием тройных комбинаций | |
| WO2009090010A1 (en) | Compositions comprising an antimuscarinic and a long-acting beta-agonist | |
| UA119773C2 (uk) | Комбінації тіотропію броміду, формотеролу і будесоніду для лікування хронічної обструктивної хвороби легень (хохл) | |
| RU2008124838A (ru) | Органические соединения | |
| US20050232871A1 (en) | Use of compounds in a dry powder inhaler | |
| TW201021792A (en) | Arformoterol and tiotropium compositions and methods for use | |
| WO2010071581A1 (en) | Pharmaceutical product comprising a muscarinic receptor antagonist and a b2-adrenoceptor agonist | |
| EP1411936B1 (en) | Use of thiazole derivatives for the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease | |
| US20130317054A1 (en) | Neuronal nicotinic agonist and methods of use | |
| AU2002317509B2 (en) | Use of thiazole deirvatives for the manufacture of a medicament for the treatment of chronic obstructure pulmonary disease | |
| AU2003200404B2 (en) | Noribogaine in the treatment of pain and drug addiction | |
| US20130317055A1 (en) | Neuronal nicotinic agonist and methods of use | |
| Syed et al. | Umeclidinium/vilanterol dry-powder inhaler in chronic obstructive pulmonary disease: a guide to its use in the EU | |
| AU2002330687A1 (en) | Inhalation compositions comprising tricyclis 5,6-dihydro-9H-pyrazolo (3,4-c)-1,2,4-triazolo (4,3-alpha) pyridines |